Researchers have discovered a new way to detect which breast cancers will respond to chemotherapy with anthracyclines. The research was recently presented at the European Breast Cancer Conference. To date, there has been no reliable means of detecting which kinds of breast cancer would respond to the drug.
Researchers conducted a meta-analysis of four large breast cancer trials that included over 3,000 patients. They found that patients with an abnormality on chromosome 17, or CEP 17, treated with anthracycline therapy were 2/3 more likely to have disease free survival and less likely to have recurrence of disease.
Even more encouraging, the test for CEP17 abnormality can be done with the same test used to detect Her2neu susceptibility - a test most breast cancer patients routinely receive.
Link to Abstract